Trametinib in metastatic melanoma

References

• Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumabin patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
   PubMed Web of Science ®Google Scholar
• World Health Organisation: Skin cancers. Available from: http://www.who.int/uv/faq/skincancer/en/index1.html
   Google Scholar
• Cancer Research UK. Melanoma Risks and Causes. Available from: http://www.cancerresearchuk.org/aboutcancer/type/melanoma/about/melanoma-risks-and-causes
   Google Scholar
• Korn EL, Liu P, Lee SJ, et al. Meta-analysis of Phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future Phase II trials. J Clin Oncol 2007;26(4):527-34
   Google Scholar
• Quirt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma: a systematic review. Curr Oncol 2007;14(1):27-33
   Google Scholar
• Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18(1):158-66
   PubMed Web of Science ®Google Scholar
• Bhatia S, Tykodi SS, Thompson JA. Treatment of Metastatic Melanoma: An Overview. Oncology (Williston Park) 2009;23(6):488-96
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004;40(12):1825-36
   PubMed Web of Science ®Google Scholar
• Eigentler TK, Caroli UM, Radny P, et al. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4(12):748-59
   PubMed Web of Science ®Google Scholar
• Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364(26):2507-16
   PubMed Web of Science ®Google Scholar
• Olszanski AJ. Current and future roles of targeted therapy and immunotherapy in advanced melanoma. J Manag Care Spec Pharm 2014;20(4):346-56
   Google Scholar
• Garbe C, Peris K, Hauschild A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2012. Eur J Cancer 2012;48(15):2375-90
   PubMed Web of Science ®Google Scholar
• Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. N Engl J Med 2011;364(26):2517-26
   PubMed Web of Science ®Google Scholar
• Hodi FS. Abstract no: LBA 24, Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma. Eur Cancer Congress 2013
   Google Scholar
• Ward FJ, Dahal LN, Khanlkar RC, et al. Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? Immunotherapy 2014;6(10):1073-84
   PubMed Web of Science ®Google Scholar
• Zhou J, Gupta M, Wu X, et al. Immunity to the vacuolar ATpase complex accessory unit ATP6S1 in patients with malignant melanoma. Cancer Immunol Res 2014;3(1):59-67
   Google Scholar
• Klinac D, Gray ES, Freeman JB, et al. Monitoring changes in circulating tumour cells as a prognostic indicator of overall survival and treatment response in patients with metastatic melanoma. BMC Cancer 2014;14:423
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhou J, Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res 2014;2(2):127-32
   PubMed Web of Science ®Google Scholar
• Keldermann S, Heemskerk B, van Tinteren H, et al. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother 2014;63(5):449-58
   Google Scholar
• Medscape Oncology. Nivolumab First-line in Melanoma: New Standard of Care? Available from: http://www.medscape.com/viewarticle/835046
   Google Scholar
• Inamdar GS, Madhunapantula SV, Robertson GP. Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail. Biochem Pharmacol 2010;80(5):624-37
   PubMed Web of Science ®Google Scholar
• Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007;445(7130):851-7
   PubMed Web of Science ®Google Scholar
• McCain J. The MAPK (ERK) Pathway, Investigational Combinations for the Treatment of BRAF-Mutated Metastatic Melanoma. P T 2013;38(2):96-108
   PubMedGoogle Scholar
• Jakob JA, Bassett RL, Chaan SN, et al. NRAS Mutation Status Is an Independent Prognostic Factor in Metastatic Melanoma. Cancer 2012;118(16):4014-23
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2012;417(6892):949-54
   Google Scholar
• Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012;366:707-14
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Trans Med 2012;10(85
   Google Scholar
• Ribas A, Kim KB, Schuchter LM, et al. BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma. J Clin Oncol 2011;29(15_Suppl
   Google Scholar
• Flaherty KT, Puzanov I Kim KB, et al. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma. N Engl J Med 2010;363(9):809-19
   PubMed Web of Science ®Google Scholar
• McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF (V600E) and BRAF (V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014;15(3):323-32
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob J, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicenter, open-label, phase 3 randomised controlled trial. Lancet 2012;380(9839):358-65
   PubMed Web of Science ®Google Scholar
• Hauschild A, Grob J, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM) (abstract). J Clin Oncol 2013;31:9010
   Google Scholar
• Curry JL, Falchook GS, Torres-Cabala CA, et al. Resistant mechanisms to BRAF inhibitor PLX4032 in melanoma. Expert Rev Dermatol 2011;6(4):355-7
   Google Scholar
• Nazarian R, Shi H, Wang Q, et al. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or NRAS upregulation. Nature 2010;468(7326):973-7
   PubMed Web of Science ®Google Scholar
• Wagle N, Emery C, Berger MF, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 2011;29(22):3085-96
   PubMed Web of Science ®Google Scholar
• Shi H, Moriceau G, Kong X, et al. Melanoma whole-exome sequencing identifies (V600E) B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012;3:724
   PubMed Web of Science ®Google Scholar
• Whittaker SR, Theurillat JP, Van Allen E, et al. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013;3:350-62
   PubMed Web of Science ®Google Scholar
• Van Allen EM, Wagle N, Sucker A, et al. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discov 2014;4(1):94-109
   PubMed Web of Science ®Google Scholar
• Shi H, Hugo W, Kong X, et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014;4(1):80-93
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF (V600E). Nature 2011;480(7377):387-90
   PubMed Web of Science ®Google Scholar
• Johannessen CM, Boehm JS, Kim SY, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010;468(7326):968-72
   PubMed Web of Science ®Google Scholar
• Su F, Bradley WD, Wang Q, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res 2012;72(4):969-78
   PubMed Web of Science ®Google Scholar
• Villanueva J, Vultur A, Lee JT, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010;18(6):683-95
   PubMed Web of Science ®Google Scholar
• Sun C, Wang L, Huang S, et al. Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma. Nature 2014;508(7494):118-22
   PubMed Web of Science ®Google Scholar
• Girotti MR1, Pedersen M, Sanchez-Laorden B, et al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma. Cancer Discov 2013;3(2):158-67
   PubMedGoogle Scholar
• Rizos H, Menzies AM, Pupo GM, et al. BRAF inhibitor resistance mechanisms in metastatic melanoma; spectrum and clinical impact. Clin Cancer Res 2014;20(7):1965-77
   PubMed Web of Science ®Google Scholar
• Joseph EW, Pratilas CA, Poulikakos PI, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A 2010;107(33):14903-8
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
   PubMed Web of Science ®Google Scholar
• Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med 2012;367(24):2316-21
   PubMed Web of Science ®Google Scholar
• Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012;30(19):2375-83
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations. N Engl J Med 2012;367(18):1694-703
   PubMed Web of Science ®Google Scholar
• Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012;366(3):207-15
   PubMed Web of Science ®Google Scholar
• Zhao Y and Adjei AA. The clinical development of MEK inhibitors. Nat Rev 2014;11:385-400
   Google Scholar
• Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62
   PubMed Web of Science ®Google Scholar
• LoRusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamics study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23(23):5281-93
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. NDA 204114 approval (online). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204114Orig1s000Approv.pdf
   Google Scholar
• Gilmartin AG, Bleam MR, Groy A, et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favourable pharmacokinetic properties for sustained in vivo pathway inhibition. Cancer Ther Preclin 2011;17(5):989-1000
   PubMed Web of Science ®Google Scholar
• King J, Nathan PD. Role of the MEK inhibitor trametinib in the treatment of metastatic melanoma. Future Oncol 2014;10(9):1559-70
   PubMed Web of Science ®Google Scholar
• Iverson C, Larson G, Lai C, et al. RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer. Cancer Res 2009;69(17):6839-47
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
   PubMed Web of Science ®Google Scholar
• Brown AP, Carlson TC, Loi CM and Graziano MJ. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration. Cancer Chemother Pharmacol 2007;59(5):671-9
   PubMed Web of Science ®Google Scholar
• Infante JR, Fecher LA, Falchook GS, et al. Safety, pharmacokinetic, and efficacy data for the oral MEK inhibitor trametinib: a phase I dose-escalation trial. Lancet Oncol 2012;13(8):772-81
   Google Scholar
• Falchook GS, Lewis KD, Infante JR, et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase I dose-escalation trial. Lancet Oncol 2012;13(8):782-9
   PubMed Web of Science ®Google Scholar
• Kim KB, Kefford R, Pavlick AC, et al. Phase II Study of the MEK1/MEK2 isnhibitor trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013;31(4):482-9
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Robert C, Hersey P, et al. Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma. N Engl J Med 2012;367(2):107-14
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Flaherty T, Hersey P, et al. Overall survival update on METRIC (NCT01245062), a randomized Phase 3 study to assess efficacy of trametinib compared with chemotherapy in patients with BRAF V600E/K mutation-positive advanced or metastatic melanoma. AbstractLBA8509, 17 – 20 November 2013, Philadelphia, PA, USA
   Google Scholar
• Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
   PubMed Web of Science ®Google Scholar
• Balmanno K, Chell SD, Gillings AS, et al. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 2009;125(10):2332-41
   PubMed Web of Science ®Google Scholar
• Nikolaev SI, Rimoldi D, Iseli C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012;44(2):133-9
   Web of Science ®Google Scholar
• Poulikos PI and Solit DB. Resistance to MEK Inhibitors: Should We Co-Target Upstream? Sci Signal 2011;4(166
   Google Scholar
• Little AS, Balmanno K, Sale MJ, et al. Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011;4(166
   Google Scholar
• Corcoran RB, Dias-Santagata D, Bergethon K, et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 2010;3(149
   Google Scholar
• Wang H, Daouti S, Li WH, et al. Identification of the MEK1(F129L) activating mutation as a potential mechanism of acquired resistance to MEK inhibition in human cancers carrying the B-Raf V600E mutation. Cancer Res 2011;71:5535-45
   PubMed Web of Science ®Google Scholar
• Yoon YK, Kim HP, Han SW, et al. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 2010;49:353-62
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Schadendorf D, Berking C, et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label Phase 2 study. Lancet Oncol 2013;14(3):249-56
   PubMed Web of Science ®Google Scholar
• UpToDate molecularly targeted therapy for metastatic melanoma. Available from: http://www.uptodate.com/contents/molecularly-targeted-therapy-for-metastatic-melanoma
   Google Scholar
• Friday BB, Yu C, Dy GK, et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008;68(15):6145-53
   PubMed Web of Science ®Google Scholar
• Robert C, Dummer R, Gutzmer R, et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013;14(8):733
   PubMed Web of Science ®Google Scholar
• Gupta A, Love S, Schuh A, et al. DOC-MEK: a double-blind randomized phase II trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma. Ann Oncol 2014;25(5):968-74
   PubMed Web of Science ®Google Scholar
• Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT). ClinicalTrials.gov Identifier: NCT01974752. Available from: https://clinicaltrials.gov/ct2/show/NCT01974752
   Google Scholar
• Gibney GT, Messina JL and Fedorenko IV, et al. Paradoxical oncogenesis – the long-term effects of BRAF inhibition in melanoma. Nat Clin Rev Oncol 2013;10(7):390-9
   PubMed Web of Science ®Google Scholar
• FDA approval for trametinib and dabrafenib. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm381451.htm
   Google Scholar
• Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 2014;371(20):1877-88
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30-9
   PubMed Web of Science ®Google Scholar
• A Study of the BRAF inhibitor dabrafenib in combination with the MEK inhibitor trametinib in the adjuvant treatment of high-risk BRAF V600 mutation-positive melanoma after surgical resection. (COMBI-AD). ClinicalTrials.gov Identifier: NCT01682083. Available from: https://clinicaltrials.gov/ct2/show/NCT01682083
   Google Scholar
• Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014;371(20):1867-76
   PubMed Web of Science ®Google Scholar
• Moriceau G, Hugo W, Hong A, et al. Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF/MEK cotargeting but result in melanoma drug addiction. Cancer Cell 2015;27(2):240-56
   PubMed Web of Science ®Google Scholar
• Gowrishankar K, Snoyman S, Pupo GM, et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 2012;132(7):1850-9
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Patnaik A, Papadopoulos KP, et al. Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother Pharmacol 2014;75(1):183-9
   Google Scholar
• Huang W, Yang AH, Matsumoto D, et al. PD0325901, a mitogen-activated protein kinase inhibitor, produces ocular toxicity in a rabbit animal model of retinal vein occlusion. J Ocul Pharmacol Ther 2009;25(6):519-30
   Google Scholar
• Trametinib With GSK2141795 in BRAF Wild-type Melanoma ClinicalTrials.gov Identifier: NCT01941927. Available from: https://clinicaltrials.gov/ct2/show/NCT01941927
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in Previously Untreated Melanoma without BRAF Mutation. N Engl J Med 2015;372(21):2006-17
   Google Scholar
• Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384(9948):1109-17
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi S, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 patients (pts) with melanoma (MEL) Oral Presentation ASCO. J Clin Oncol 2014
   Google Scholar
• Dummer R, Daud A, Puzanov I, et al. A randomised controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory melanoma. J Transl Med 2015;13(Suppl 1
   Google Scholar
• Weber J. Abstract LBA3_PR - A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA4 therapy. Presidential Symposium 2. ESMO Congress 2014. Madrid, Spain
   Google Scholar
• Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013;369(2):122-33
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443-54
   PubMed Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med 2012;366(26):2517-19
   PubMed Web of Science ®Google Scholar
• Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL). J Clin Oncol 2014;32:5s
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). J Clin Oncol 2015;33(Suppl): abstract LBA1
   Google Scholar
• NICE proposes ipilimumab as a first treatment for advanced skin cancer. Available from: http://www.nice.org.uk/news/press-and-media/nice-proposes-ipilimumab-as-a-first-treatment-for-advanced-skin-cancer
   Google Scholar
• Ascierto P, Grimaldi AM, Acquavella N, et al. Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012”. J Transl Med 2013;11:137
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oxnard GR, Sima CS, et al. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011;17(19):6298-303
   PubMed Web of Science ®Google Scholar
• Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365-6
   Google Scholar
• Puzanov I, Callahan MK, Linette GP, et al. Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation–positive unresectable or metastatic melanoma (MM). J Clin Oncol 2014;32:5s
   Web of Science ®Google Scholar
• Palmer SR, Erickson LA, Ichetovkin I, et al. Circulating Serologic and Molecular Biomarkers in Malignant Melanoma. Mayo Clin Proc 2011;86(10):981-90
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Kalos M, Schaer DA, et al. Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types. Clin Cancer Res 2013;19:1009
   PubMed Web of Science ®Google Scholar